Journey Medical Corporation will announce Q3 2025 financial results on November 12, with a conference call at 4:30 p.m. ET.
Quiver AI Summary
Journey Medical Corporation has announced that it will release its financial results for the third quarter of 2025 after the market closes on November 12, 2025. Following this, management will hold a conference call and audio webcast at 4:30 p.m. ET on the same day, with details provided for participation via telephone and online. Journey Medical specializes in selling FDA-approved prescription products for dermatological conditions and currently markets eight such drugs. The company, founded by Fortress Biotech, is based in Scottsdale, Arizona, and aims to offer efficient sales and marketing for its products. Additional information can be found on their website, and contact details for the company and media relations are also provided.
Potential Positives
- Journey Medical Corporation is set to release its third quarter 2025 financial results, indicating a commitment to transparency and communication with investors.
- The scheduled conference call provides an opportunity for stakeholders to engage directly with management, fostering investor relations.
- The company emphasizes its focus on FDA-approved products, which highlights adherence to regulatory standards and potentially increases investor confidence.
Potential Negatives
- Announcement of upcoming financial results could indicate that the company is facing scrutiny regarding its performance, raising concerns among investors.
- Failure to provide any preliminary financial information in the release may suggest a lack of transparency or indicate that results are not favorable.
- Potentially limited engagement with investors and stakeholders due to the requirement for prior registration to participate in the conference call, which could deter attendance.
FAQ
When will Journey Medical release its third quarter 2025 financial results?
Journey Medical will release its third quarter 2025 financial results on November 12, 2025, after U.S. market close.
How can I participate in the Journey Medical conference call?
To participate in the call, dial 1-866-777-2509 for U.S. callers or 1-412-317-5413 for international callers, about 10 minutes early.
Where can I find the webcast of the financial results call?
The webcast will be available on the News and Events page of Journey Medical's website and will remain accessible for 30 days.
What type of products does Journey Medical focus on?
Journey Medical primarily markets FDA-approved prescription pharmaceutical products for treating dermatological conditions.
Who founded Journey Medical Corporation?
Journey Medical was founded by Fortress Biotech, Inc. and is located in Scottsdale, Arizona.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DERM Hedge Fund Activity
We have seen 41 institutional investors add shares of $DERM stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 491,108 shares (+922.5%) to their portfolio in Q2 2025, for an estimated $3,526,155
- CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. removed 338,050 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,427,199
- ESSEX INVESTMENT MANAGEMENT CO LLC added 228,203 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,638,497
- WASATCH ADVISORS LP added 221,456 shares (+23.8%) to their portfolio in Q2 2025, for an estimated $1,590,054
- VANGUARD GROUP INC added 192,727 shares (+51.8%) to their portfolio in Q2 2025, for an estimated $1,383,779
- GEODE CAPITAL MANAGEMENT, LLC added 148,612 shares (+130.7%) to their portfolio in Q2 2025, for an estimated $1,067,034
- UBS GROUP AG added 141,713 shares (+831.7%) to their portfolio in Q2 2025, for an estimated $1,017,499
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DERM Analyst Ratings
Wall Street analysts have issued reports on $DERM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 08/13/2025
- B. Riley Securities issued a "Buy" rating on 07/30/2025
To track analyst ratings and price targets for $DERM, check out Quiver Quantitative's $DERM forecast page.
$DERM Price Targets
Multiple analysts have issued price targets for $DERM recently. We have seen 3 analysts offer price targets for $DERM in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $13.0 on 08/25/2025
- Thomas Flaten from Lake Street set a target price of $13.0 on 08/13/2025
- Kalpit Patel from B. Riley Securities set a target price of $12.0 on 07/30/2025
Full Release
SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10204065/100324a2b1b . Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com , and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com
.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
[email protected]
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]
